<p><strong>Solid Phase Extraction (SPE) is one of the most highly selective sample preparation methods, meaning that the targeted analytes and their matrices must be considered when choosing the correct SPE sorbent and format. Drying down the sorbent before elution is an important step.</strong></p><ul><li>Wash solvents are used to flush out unwanted compounds (i.e., contaminants). If the wash solvent is not completely removed, then residual wash solvent could contaminate the final elution.</li><li>If you do not dry the SPE sufficiently, it could make the final solution less concentrated and result in a reduction in sensitivity.</li><li>Drying helps physically break down the interactions between the sorbent and analyte for a more concentrated extract.</li></ul><p>After the wash solvent has been passed through the cartridge, continue to apply negative pressure (vacuum) or positive pressure. Use this pressure to dry the cartridge for 2 to 5 minutes (or until dry). Turn off the pressure and wipe the tips of the manifold needles to remove any residual solvent.</p><h5><strong>Notes</strong></h5><ol><li><strong>Reproducibility:</strong> Drying removes traces of residual sample/matrix and wash solvent from the sorbent. This produces a more concentrated final extract with a consistent volume and composition and yields better reproducibility and higher recoveries.</li><li><strong>Immiscibility:</strong> Drying is especially critical when using elution solvents that are immiscible with water (e.g. hexane, ethyl acetate, and methylene chloride). Residual water in the sorbent bed may prevent dissolution of the analyte in the elution solvent, resulting in low recoveries and irreproducibility.</li><li><strong>Over-drying: </strong>Avoid over-drying the sorbent, since in some cases, analyte recovery may decrease with excessive vacuum or drying times above 5 minutes. Dry cartridges look distinctly different from moist ones. Make a note of the cartridge appearance before and after conditioning. Also, you could touch the cartridge while it is drying; wet cartridges feel colder than dry cartridges.&nbsp;</li></ol>

Why Is It Necessary to Dry the SPE Sorbent Before Elution?

<h3><strong>Mastering Ion-Pair Reversed-Phase Chromatography for Oligonucleotide Analysis</strong></h3><h4><strong>Why Purity Is Critical in the Oligonucleotide Era</strong></h4><p>Oligonucleotides — short, synthetic strands of DNA or RNA — are central to modern biotechnology. They power gene therapies, advanced diagnostics, and cutting-edge molecular research. However, before these molecules can be used in clinical or research settings, their purity and structural integrity must be thoroughly verified. High-resolution chromatographic analysis plays a crucial role in ensuring quality and safety.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Figure_1_Separation_Example_of_Oligonucleotides_5577514561.jpg" alt="KNAUER: Figure 1 - Separation Example of Oligonucleotides." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Figure_1_Separation_Example_of_Oligonucleotides_5577514561.jpg 245w," sizes="100vw" width="1024" height="368"></p><h4><strong>Understanding Ion-Pair Reversed-Phase (IP-RP) Chromatography</strong></h4><p>For scientists involved in oligonucleotide synthesis and characterization, Ion-Pair Reversed-Phase Chromatography (IP-RP) is one of the most effective analytical tools available.</p><p>Unlike separation techniques that rely solely on charge differences, IP-RP combines:</p><ul><li>Ionic interactions</li><li>Hydrophobic interactions</li></ul><p>This dual retention mechanism enables exceptional resolution — even for oligonucleotides that differ by only a single nucleotide or subtle chemical modification. Whether assessing synthesis efficiency or purifying therapeutic-grade material, IP-RP provides reliable, reproducible separations.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Figure_2_Overview_of_IP_RP_Mode_prinicple_ecd54b6e9c.jpg" alt="KNAUER: Figure 2 - Overview of IP-RP Mode prinicple." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Figure_2_Overview_of_IP_RP_Mode_prinicple_ecd54b6e9c.jpg 245w," sizes="100vw" width="1024" height="456"></p><h4><strong>The Principle Behind Ion-Pairing</strong></h4><p>Oligonucleotides possess a highly negatively charged phosphate backbone. In a traditional reversed-phase system, such hydrophilic, charged molecules would show little retention.</p><p>IP-RP overcomes this limitation by introducing a positively charged ion-pairing reagent into the mobile phase. The cation associates with the negatively charged oligonucleotide, forming a transient ion pair with increased hydrophobic character. This modified complex can now interact with the hydrophobic stationary phase.</p><p>Retention strength depends on:</p><ul><li>The hydrophobicity of the ion-pair reagent</li><li>The strength of ionic interaction</li><li>The applied organic gradient</li></ul><p>During gradient elution (commonly using acetonitrile), analytes are released in a controlled manner according to size, sequence, and chemical modifications.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Figure_3_Ion_Pair_Reversed_Phase_Principle_9a4fcd12f2.jpg" alt="KNAUER: Figure 3 - Ion-Pair Reversed Phase Principle." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Figure_3_Ion_Pair_Reversed_Phase_Principle_9a4fcd12f2.jpg 245w," sizes="100vw" width="1024" height="393"></p><h4><strong>Choosing the Right Ion-Pair Reagent</strong></h4><p>Successful IP-RP separation depends heavily on selecting an appropriate ion-pair reagent. Two key factors determine retention behavior:</p><ol><li>Alkyl chain length</li><li>Charge density</li></ol><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Figure_4_Ion_Pair_Classification_eaad172a4e.jpg" alt="KNAUER: Figure 4 - Ion-Pair Classification." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Figure_4_Ion_Pair_Classification_eaad172a4e.jpg 245w," sizes="100vw" width="1024" height="398"></p><h4><strong>Strong Cationic Ion-Pair Reagents</strong></h4><p>Ion-pair reagents with longer alkyl chains provide stronger hydrophobic interactions and increased retention. A widely used example is tetrabutylammonium (TBA⁺), frequently applied for strongly retained anionic analytes.</p><p>These reagents are particularly useful when high retention strength is required.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Table_1_Strong_Cationic_Ion_Pair_Reagents_8dbf00c57e.jpg" alt="KNAUER: Table 1 - Strong Cationic Ion-Pair Reagents." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Table_1_Strong_Cationic_Ion_Pair_Reagents_8dbf00c57e.jpg 245w," sizes="100vw" width="1024" height="396"></p><h4><strong>Volatile (Weaker) Ion-Pair Reagents</strong></h4><p>Short-chain ion-pair reagents generate weaker retention but offer a significant advantage: compatibility with LC–MS detection.</p><p>Triethylammonium (TEA⁺) is among the most commonly used reagents for oligonucleotide analysis, particularly when mass spectrometric detection is involved. Other options, such as diisopropylethylammonium (DIEA⁺), are also widely applied, often combined with HFIP to enhance MS performance.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Table_2_Weak_Cationic_Ion_Pair_Reagents_6332a4975e.jpg" alt="KNAUER: Table 2 - Weak Cationic Ion-Pair Reagents." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Table_2_Weak_Cationic_Ion_Pair_Reagents_6332a4975e.jpg 245w," sizes="100vw" width="1024" height="283"></p><h4><strong>Building an IP-RP Method for Oligonucleotides</strong></h4><p>Developing a robust IP-RP method follows a logical sequence:</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Table_3_IP_RP_Method_Step_Procedure_for_Oligos_c2216c24a0.jpg" alt="KNAUER: Table 3 - IP-RP Method Step Procedure for Oligos." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Table_3_IP_RP_Method_Step_Procedure_for_Oligos_c2216c24a0.jpg 245w," sizes="100vw" width="1024" height="304"></p><h5><strong>1. Characterize the Analyte</strong></h5><p>Oligonucleotides typically contain 10–50+ nucleotides and exhibit high negative charge density. This necessitates a suitable cationic partner such as TEA⁺ or DIEA⁺.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Figure_5_Cationic_Ion_Pair_Principle_for_Oligonucleotides_cb2dfb7457.jpg" alt="KNAUER: Figure 5 - Cationic Ion-Pair Principle for Oligonucleotides." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Figure_5_Cationic_Ion_Pair_Principle_for_Oligonucleotides_cb2dfb7457.jpg 245w," sizes="100vw" width="512" height="320"></p><h5><strong>2. Select the Column</strong></h5><p>Use a reversed-phase column with:</p><ul><li>Large pore size (≈300 Å)</li><li>Appropriate internal diameter</li></ul><p>These parameters support the so-called “ON–OFF” retention mechanism — a bind-and-elute behavior where analytes are strongly retained until the gradient triggers rapid elution.</p><h5><strong>3. Optimize the Mobile Phase</strong></h5><p>A typical starting condition includes:</p><ul><li>10 mM TEA buffer at pH ~7</li><li>Acetonitrile as organic modifier</li></ul><p>Gradient programs from approximately 5% to 50% organic solvent over 15–30 minutes are commonly effective for complex oligonucleotide mixtures.</p><h5><strong>4. Adjust Retention Strength if Needed</strong></h5><p>To increase retention:</p><ul><li>Raise ion-pair concentration (up to ~100 mM if required)</li><li>Select a more hydrophobic ion-pair reagent</li></ul><h5><strong>5. Validate the Method</strong></h5><p>Ensure robustness, sensitivity, and reproducibility by carefully evaluating:</p><ul><li>UV chromatograms</li><li>MS traces</li><li>Peak shape and resolution</li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Figure_6_UV_MS_traces_of_IP_RP_Oligonucleotide_Analysis_81faf4e9f0.jpg" alt="KNAUER: Figure 6 - UV-MS traces of IP-RP Oligonucleotide Analysis." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Figure_6_UV_MS_traces_of_IP_RP_Oligonucleotide_Analysis_81faf4e9f0.jpg 245w," sizes="100vw" width="1024" height="365"></p><h4><strong>Why IP-RP Is Considered the Gold Standard</strong></h4><p>Ion-Pair Reversed-Phase Chromatography uniquely combines the resolving power of reversed-phase LC with the ability to retain highly polar, charged biomolecules.</p><p>Its advantages include:</p><ul><li>Tunable selectivity</li><li>Compatibility with UV and MS detection</li><li>Scalability from analytical to preparative workflows</li><li>Applicability from research to pharmaceutical production</li></ul><p>By transforming highly charged oligonucleotides into hydrophobic ion-pair complexes, IP-RP enables precise and reproducible separations that would otherwise be impossible in conventional reversed-phase systems.</p><p>For these reasons, IP-RP is widely regarded as the benchmark technique for oligonucleotide analysis.</p><h4><strong>Final Thoughts</strong></h4><p>Mastering IP-RP is less intimidating than it may seem. A successful method comes down to:</p><ul><li>Selecting the right ion-pair reagent</li><li>Choosing a suitable column</li><li>Optimizing gradient conditions</li><li>Fine-tuning temperature and concentration parameters</li></ul><p>With thoughtful method development, IP-RP delivers sharp peaks, clean separations, and reliable performance — fully compatible with modern mass spectrometry workflows and ready to meet the demands of advanced oligonucleotide analysis.</p>

Oligos Made Easy - Part 3: IP-RP

News from LabRulezLCMS Library - Week 08, 2026

Article

Application

Academy

Video

Presentation

Science and research

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, government and academic laboratories.

Phenomenex

Based in Berlin, KNAUER is a medium-sized, owner-managed company that has been serving the sciences since 1962. We develop and manufacture scientific instruments of superior quality for liquid chromatography, including: Analytical HPLC/UHPLC, Preparative HPLC, Fast protein liquid chromatography (FPLC), Multi-column chromatography/Simulated moving bed (SMB) chromatography. High pressure dosing, in-line detection systems, and osmometry are additional business areas.

KNAUER

Separation Science

Technology Networks

Bruker

Thermo Fisher Scientific

SelectScience

SCIEX

Waters Corporation

<div><div container-id="cq-colctrl-lt0" comp-id="A1"><div><p><strong>Join us for an exciting webinar where we introduce the new mass spectrometry (MS) functionalities in Chromeleon 7.4 software. This session will provide an overview of the latest features and enhancements, along with practical tips and tricks to optimize your MS workflows. Whether you are a seasoned user or new to Chromeleon CDS, this webinar will equip you with the knowledge to leverage the new MS capabilities, streamline your processes, and achieve more accurate results.</strong></p><h5><strong>Key takeaways:</strong></h5><ul><li>Discover the new MS functionalities and enhancements in Chromeleon 7.4 software</li><li>Learn practical tips and tricks for optimizing MS workflows</li><li>Understand how to integrate and configure MS settings for improved performance</li><li>Get answers to your specific questions during the live Q&amp;A session</li></ul><h5><strong>Who should attend:</strong></h5><ul><li>Chromeleon CDS users looking to upgrade their MS capabilities</li><li>Laboratory analysts and technicians working with mass spectrometry</li><li>Quality control and assurance professionals seeking to enhance MS workflows</li><li>Anyone interested in learning more about the new MS features in Chromeleon 7.4 software</li></ul><p><i>Don't miss this opportunity to stay ahead with the latest MS functionalities and optimize your workflows in Chromeleon 7.4. Register now to secure your spot!</i></p><blockquote><p><strong>Presenter: </strong>Kimy Young (Senior Manager, Software Product Specialists, Thermo Fisher Scientific)</p><p>Kimy Young is the Senior Manager of software product specialists at Thermo Fisher Scientific. She has been with Thermo Fisher since November 2015. Her background includes administration of Chromeleon CDS, laboratory information management systems (LIMS), Quality Assurance (QA), and IT projects.</p><p><strong>Presenter: </strong>Juan Carmona (Chromeleon CDS Specialist, Thermo Fisher Scientific)</p><p>Juan Carmona is a Chromeleon Specialist at Thermo Fisher Scientific based out of Pflugerville, TX. He has been with Thermo Fisher Scientific for over 15 years. At Thermo Fisher Scientific, he is currently focusing on expanding the customer base using Chromeleon CDS for small networks and enterprise deployments. Prior to joining this group, he was part of the GC/GCMS Center of Excellence team providing support for the product line.</p><p><strong>Presenter: </strong>Monica Driscoll (Regional Marketing Specialist, Thermo Fisher Scientific)</p></blockquote></div></div></div>

Thermo Fisher Scientific: Chromeleon CDS webinar series

Mastering mass spectrometry with Chromeleon CDS: Expert tips and tricks

Discover new MS capabilities in Chromeleon 7.4 and learn how to streamline workflows for better performance. Join the live Q&A with Thermo Fisher experts.

Mastering MS with Chromeleon CDS: Expert tips and tricks

<div><p><strong>Join us for an insightful webinar on the PIPAc project, an innovative approach to pharmaceutical manufacturing that integrates AI, NMR, flow chemistry, and 3D-printed modular reactors. Attendees will explore how AI-driven process control optimizes chemical reactions in real time, while in-line NMR provides precise monitoring of active pharmaceutical ingredient (API) synthesis. Continuous flow chemistry combined with compact, 3D-printed reactors enable mobile, resource-efficient production, supporting rapid scale-up and flexible deployment. Gain in-depth insights into the convergence of automation, analytical technologies, and advanced reactor design shaping modern pharmaceutical production.</strong></p><h5><strong>Key Learning Points</strong></h5><ul><li><strong>Enhanced Process Control: </strong>Learn how AI, NMR, and PAT enable real-time monitoring, optimizing reactions and ensuring efficient, reliable API production.</li><li><strong>Scalable and Flexible Production: </strong>Understand how modular 3D-printed reactors and continuous flow chemistry support rapid scale-up and mobile manufacturing.</li><li><strong>Innovative Applications:</strong> Explore advanced applications of flow chemistry, 3D-printed reactors, and AI-driven analytics to drive innovation and improve pharmaceutical API processes.</li></ul><h5><strong>What to Expect</strong></h5><p>Discover how the PIPAc project integrates AI, NMR, flow chemistry, and 3D-printed reactors for compact, mobile API manufacturing. Learn about real-time process monitoring, continuous flow optimization, modular reactor design, and case studies showcasing efficient, scalable, and safe pharmaceutical production, providing actionable insights for modern API synthesis.</p><h5><strong>Who should attend?</strong></h5><p>This webinar is designed for pharmaceutical scientists, bioprocess engineers, and quality assurance professionals, as well as anyone involved in pharmaceutical manufacturing and development. Attendees will gain practical insights to enhance process control, ensure product quality, and explore innovative NMR, PAT, and AI applications.</p><blockquote><p><strong>Presenter:</strong> Alejandro Bara-Estaún, PhD (Solution Product Manager for (bio)Process Analytical Technology, Bruker Biospin)</p><p>Alejandro Bara Estaun obtained his Ph.D. in Inorganic Chemistry at the University of Bath (UK) in collaboration with Bristol University and Evonik (Germany). He then undertook a two-year postdoctoral position at Bruker, leading the PIPAc project in collaboration with Alysohpil, Novalix, and De Dietrich. Recently, he transitioned into the role of Solution Product Manager for (bio)Process and Process Analytical Technology within Bruker’s Biopharma and Applied (BPA) division.</p><p><strong>Presenter:</strong> Philippe Robin (Co-founder and CEO of Alysophil)</p><p>Philippe Robin is the co-founder and CEO of Alysophil, a Strasbourg-based company developing solutions in continuous-flow chemistry enhanced by artificial intelligence for process control. Alysophil aims to improve the efficiency and sustainability of chemical production. Under his leadership, the company has launched projects such as Chempocket, modular micro-factories designed for flexible chemical synthesis, and PIPAc, a program dedicated to pharmaceutical processes, carried out with partners including De Dietrich, Bruker, and Novalix. Philippe Robin focuses on applying new technologies to support the chemical industry’s transition toward more flexible and responsible production models.</p><p><strong>Presenter:</strong> Luis Carrillo (Managing Director, De Dietrich France Dijon SAS)</p><p>Luis Carrillo is the Managing Director of De Dietrich Group’s subsidiary in Dijon, dedicated to developing engineering solutions through the integration of both in-house and third-party products. Dijon also serves as the hub for the Group’s innovation program, within which the PIPA’c project plays a pivotal role as a cornerstone for the future commercial development of these solutions. A chemist by training, Luis earned his degree from the University of Barcelona (Spain) and later completed a Master at IESE Business School. Luis Carrillo has been with the De Dietrich Group for more than 10 years, holding various positions across the organization. Luis Carrillo is committed to advancing sustainable innovation and strengthening the Group’s leadership in chemical engineering solutions. &nbsp;</p><p><strong>Presenter:</strong> Guillaume Bentzinger, PhD (Flow &amp; Process department, Novalix)</p><p>Guillaume Bentzinger joined Novalix as a Junior Project Manager in 2018 in the Synthetic Chemistry department. In 2019, he transitioned to the Process &amp; Flow department where he advanced to Project Manager and has been actively contributing to the development of flow chemistry at Novalix. He is leading the development of the chemistry under flow conditions for the PIPAc project. Guillaume Bentzinger studied organic chemistry in Strasbourg, at the IUT Robert Schuman Technical Institute, and later at the European School of Chemistry, Polymers and Materials (ECPM). In 2016, he completed his PhD in medicinal chemistry under the supervision of Professor Pascal Sonnet and Dr. Alexandra Dassonville-Klimpt at the University of Picardie Jules Verne in Amiens. In 2017, he pursued postdoctoral research in medicinal chemistry at Almac Discovery and the University of Belfast, under the supervision of Dr. Hugues Miel.</p></blockquote></div>

Bruker: Flow Chemistry Meets AI and NMR for Next-Gen API Production

Flow Chemistry Meets AI and NMR for Next-Gen API Production

Webinar on PIPAc: AI, NMR, flow chemistry & 3D-printed reactors for scalable, flexible API manufacturing with real-time monitoring and process optimization.

<div><p><strong>Aggregation and the formation of oligomers and high molecular weight species (HMWS) remain critical challenges in biotherapeutic development. Left unchecked, they can impact product efficacy, safety, and regulatory approval. To that end, regulators suggest the use of orthogonal techniques that can detect and characterize particles of different sizes.</strong></p><p>In this GEN webinar, our expert speaker will present a systematic approach for identifying oligomers, HMWs, and aggregates in biotherapeutics manufacturing. You will learn about a high-throughput workflow integrating dynamic light scattering (DLS) and background membrane imaging (BMI) to characterize particles across size regimes, from nanometers to sub-visible and beyond.</p><h5><strong>Key Learning Objectives:</strong></h5><ul><li>How oligomers and HMWs compromise stability, safety, and regulatory approval in today’s biologics</li><li>How orthogonal detection methods deliver complementary quantitative and qualitative insights into stability</li><li>Practical strategies for monitoring aggregation from early formulation through development and manufacturing</li></ul><blockquote><p><strong>Presenter:</strong> Karessa White, Ph.D. (Waters Corporation)</p><p>Dr. Karessa White is a Sr. Market Application Scientist at Waters Corporation. She obtained her Ph.D. from the University of Florida in Communication Sciences and Disorders emphasizing auditory neuroscience. After spending time serving her country as a United States Army Medical Service Officer, Karessa now leverages her expertise and training in molecular biology and analytical science to help biotherapeutic developers create safe and stable drugs.</p><p><strong>Presenter:</strong> Udayabagya (Bud) Halim (Waters | Wyatt Technology)</p><p>Bud Halim is a Senior Marketing Analyst at Wyatt Technology, bringing a wealth of scientific expertise to the analytical instrumentation field. He earned both his B.S. and Ph.D. in Physical Chemistry from UCLA, where he first developed his passion for science. Bud began his career in academia as an adjunct professor, teaching Biochemistry, Analytical Chemistry, and Physical Chemistry, while also contributing as an editor and author to several laboratory manuals. He later transitioned into the scientific instrumentation industry, serving in roles such as applications scientist, where he gained hands-on experience in the characterization of peptides, traditional biologics, lipid nanoparticles (LNPs), and viral vectors.</p></blockquote></div>

Waters Corporation: Hidden Threats: High-Throughput Strategies to Detect Aggregates in Biotherapeutics

Hidden Threats: High-Throughput Strategies to Detect Aggregates in Biotherapeutics

Webinar on detecting aggregates in biotherapeutics. Discover high-throughput DLS and BMI workflows to ensure safety, stability, and regulatory compliance.

Hidden Threats: Detecting Aggregates in Biotherapeutics

<p><strong>Unlock the full potential of your LC-MS system with Thermo Scientific™ Chromeleon™ software features. This webinar will demonstrate the system suitability test with intelligent run control (SST/IRC) capabilities, which provides a robust framework for maintaining the integrity and reliability of LC-MS datasets. We will showcase this functionality in relation to clinical research and forensic toxicology laboratories, saving precious sample and time for data review.&nbsp;</strong></p><p>By automating the evaluation of critical operational conditions and data processing results, the software enables real-time decision-making to address potential issues, such as carryover and quantification inaccuracies. This not only safeguards the quality of the data but also enhances laboratory efficiency and productivity. The ability to define and execute automated responses to test case outcomes ensures that the LC-MS system operates consistently and within expected parameters, ultimately leading to more accurate and reliable analytical results.</p><p>Don't miss this opportunity to elevate your LC-MS operations and achieve greater precision in your research.</p><h5><strong>Learning Objectives:</strong></h5><ul><li>Discover how Chromeleon software automates the evaluation of critical operation and data processing metrics</li><li>Interpret how automated responses to failed test criteria—such as carryover or inconsistent chromatography—can reduce downtime and improved confidence in the analytical results</li><li>Review practical guidance on configuring and implementing SST/IRC functionality within Chromeleon software</li></ul><blockquote><p><strong>Presenter:</strong> Kimy Young (Senior Manager, Software Product Specialists; Thermo Fisher Scientific)</p><p>Kimy Young is a highly experienced Chromeleon software specialist with over 17 years of expertise. She spent over seven years as a customer and software administrator for the first environmental company to adopt an enterprise Chromeleon solution, followed by eight years as a software sales specialist. Currently, she serves as the Senior Manager of Software Product Specialists. Kimy excels in designing Chromeleon solutions, architectures, and reports, supporting a wide range of industries, including pharma/biopharma, environmental, food and beverage, oil and gas, and manufacturing.</p><p><strong>Presenter: </strong>Dr. Jingshu Guo (Senior Product Applications Specialist; Thermo Fisher Scientific)</p><p>Dr. Jingshu Guo is a trained mass spectrometrist with over 10 years of experience in LC-MS-based qualitative and quantitative analyses of small molecules, nucleosides, peptides, and intact protein. After joining Thermo Fisher Scientific, she worked on the method development, implementation, and optimization in clinical and toxicology-related fields. One of her current focuses is to develop fast quantification methods in small molecules, such as biomarkers, therapeutic drugs, and drugs of abuse in biofluids using LC coupled to triple quadrupole MS or high-resolution MS, and LC-free MS platforms.&nbsp;</p></blockquote>

Thermo Fisher Scientific: Safeguard dataset quality in LC-MS analysis with system suitability testing and intelligent run control (SST/IRC)

Safeguard dataset quality in LC-MS analysis with system suitability testing and intelligent run control (SST/IRC)

Unlock the full potential of your LC-MS system with Thermo Scientific™ Chromeleon™ software features. 

Safeguard dataset quality in LC-MS analysis with SST/IRC

<div><h4><strong>Strategies to Reduce Risk When Performing LC Method Adjustments</strong></h4><p>As laboratories face evolving materials, instrumentation, and regulatory expectations, understanding the circumstances that justify changing methods is essential. This is especially relevant as more methods are developed on higher performing UHPLC instruments and high-efficiency, sub-2-µm particle columns. These UHPLC methods are suitable for many systems, however, method adjustment may be needed to perform the analysis on HPLC systems. While there are guidelines for performing method adjustments, additional factors, including instrumentation, can impact the performance of the scaled method.</p><p>This three-part webinar series on analytical method adjustment in pharmaceutical analysis is designed to provide practical insights into when and how to adapt validated analytical methods.</p><h5><strong>Topics include:</strong></h5><ul><li>How to assess risk when performing method adjustments and identify some control strategies for more common method and instrument contributors</li><li>How to adapt an analytical method, focusing on the impact of LC instrument characteristics and their impact on scaling from UHPLC to HPLC Columns</li><li>Practical tips and strategies to consider when adjusting LC methods across a variety of instruments</li></ul><p>This series is ideal for analysts, QA professionals, and method developers seeking actionable guidance rooted in real-world lab experience.</p><h4><strong>Session 2: Considerations for Method Adjustment Across UHPLC and HPLC Systems</strong></h4><p>This session will explore a real-world example of method adjustment, with a focus on scaling from UHPLC to HPLC, with appropriate instrumentation. We will review the key principles of scaling a method, including column selection and geometric scaling calculations. The impact of a wide range of instrument characteristics will also be demonstrated, including but not limited to delay volume and extra-column dispersion. Assessment of the scaled method will focus on meeting method suitability criteria when adjusting methods across equipment platforms.</p><blockquote><p><strong>Presenter:</strong> Andrew Steere (Evaluation Scientist II, Waters Corporation)</p><p>Andrew Steere is an Evaluation Scientist II at Waters Corporation. He works in the Validation and Competitive Analysis Group within the LC-MS business unit. He graduated from Marist College in 2018 with a degree in Chemistry. Prior to starting at Waters in 2021, he worked in a CRO and primarily focused on LC-TUV/MS and GC-FID/MS instrumentation in cGMP and R&amp;D environments. His current work focuses on evaluating the performance of LC instrumentation across the market through application development and testing.</p></blockquote></div>

Waters Corporation: Strategies to Reduce Risk When Performing LC Method Adjustments

Session 2: Considerations for Method Adjustment Across UHPLC and HPLC Systems

This session will explore a real-world example of method adjustment, with a focus on scaling from UHPLC to HPLC, with appropriate instrumentation. 

Considerations for Method Adjustment Across UHPLC and HPLC

<div><div container-id="cq-colctrl-lt0" comp-id="A1"><div><p><strong>PFAS testing demands precise, reliable, and contamination-free sample preparation across diverse matrices. This webinar introduces the Biotage® PrepXpert-8, the newest addition to the Biotage® automated solid phase extraction (SPE) portfolio, designed to deliver unmatched versatility for PFAS analysis. Attendees will begin with a comparative overview of three Biotage® automation platforms—the &nbsp;Biotage® Extrahera™ family, Biotage® PrepXpert-8, and Biotage® Horizon 5000—before exploring the innovative features unique to the &nbsp;Biotage® PrepXpert-8.</strong></p><p>The session will cover practical applications for key PFAS methods, including DIN EN 17892, EPA 1633A, 533, and 537.1, supported by performance data on method detection limits, precision, and accuracy. We will also examine the role of advanced sorbent chemistries, such as EVOLUTE® PFAS+ and EVOLUTE® WAX/GCB, in achieving low background levels and robust recoveries.</p><p>Beyond analytical performance, the webinar will highlight operational benefits for laboratories—showing how automation, higher throughput, and integrated cleaning procedures can reduce contamination risks, eliminate carryover, and boost daily efficiency. Join us to discover how the Biotage® PrepXpert-8 completes the Biotage® SPE portfolio and sets a new benchmark for automated PFAS sample preparation.</p><h5><strong>By attending this webinar, you will learn:</strong></h5><ul><li><strong>Explore the capabilities of three leading automated SPE platforms</strong>—Biotage® Extrahera™ family, Biotage® PrepXpert-8, and Biotage® Horizon 5000—and understand how each integrates into different PFAS sample preparation.</li><li><strong>Gain actionable insights into PFAS applications</strong> (DIN EN 17892, EPA 1633A, 533, and 537.1) using Biotage® PrepXpert-8, supported by performance data on detection limits, precision, and accuracy.</li><li><strong>Learn strategies to boost laboratory efficiency</strong> through automation, optimized sorbent chemistries (EVOLUTE® PFAS+ and EVOLUTE® WAX/GCB), and automated cleaning protocols that minimize contamination and carryover.</li></ul><blockquote><p><strong>Presenter: </strong>Evan Walters (MSc) (Market Segment &amp; Applications Manager, Biotage)</p><p>Evan Walters is a Regional Market Segment and Applications Manager for Biotage and has been with the company for 7 years. He is passionate about science and analytical chemistry in the environmental, food and agriculture market segments. He has previously held roles as an environmental chemist, geochemist, and technical sales representative. Walters received a Master of Science in Geochemistry from Southern Illinois University.</p></blockquote></div></div></div>

SeparationScience: Automated Sample Prep: Transforming the Future of PFAS Analysis

Automated Sample Prep: Transforming the Future of PFAS Analysis

Biotage® PrepXpert-8, the newest addition to the Biotage® automated SPE portfolio, designed to deliver unmatched versatility for PFAS analysis.

Automated Sample Prep: Future of PFAS Analysis

<div><p>Covalent inhibitors are regaining attention in drug discovery for their enhanced potency, selectivity and their ability to tackle challenging targets.</p><p>&nbsp;</p><p><strong>Our expert speakers will showcase Evotec’s innovative strategy for identifying covalent hits using high-throughput mass spectrometry. By attending, you’ll learn how intact protein and peptide-based assays can rapidly highlight promising binders, precisely mapping their binding sites. Our speakers will also demonstrate the power of chemoproteomic profiling in live cells to validate target engagement and selectivity.</strong></p><p>Join this webinar to discover how integrating these complementary approaches can reduce off-target risks, accelerate timelines and improve confidence in progressing from hit to lead – helping researchers strengthen their discovery pipeline.</p><h4><strong>Attend this webinar to:</strong></h4><ul><li>Explore the background of covalent inhibitors and their unique benefits in modern drug discovery</li><li>Learn how high-throughput mass spectrometry (MS) accelerates covalent hit identification</li><li>Gain an insight into site-specific analysis using peptide mapping and intact protein MS</li><li>Take a dive into advanced chemoproteomic strategies for hit validation</li></ul><blockquote><p><strong>Presenter:</strong> Julien Parra, PhD (Senior Research Scientist, High-Throughput Biology &amp; Screening at Evotec)</p><p>Currently serving as a senior research scientist in the high-throughput biology and screening team at Evotec in Toulouse, Dr. Julien Parra is a highly experienced mass spectrometry specialist with over a decade of experience in analytical chemistry, proteomics and structural biology. Julien earned his PhD in analytical chemistry from the Université Évry Paris-Saclay and later joined the Institute of Pharmacology and Structural Biology as a postdoctoral researcher. His work is characterized by a deep understanding of protein chemistry, a strong command of mass spectrometry instrumentation and a passion for translating complex data into biological insights.</p><p><strong>Presenter:</strong> Violette Gautier, PhD (Research Scientist, Proteomics at Evotec)</p><p>Dr. Violette Gautier is a proteomics research scientist with over fifteen years of experience in proteomics, including more than nine years in the pharmaceutical industry. At Evotec, she specializes in chemoproteomics approaches such as activity-based protein profiling and cysteine proteomics profiling. She contributes to covalent drug discovery programs by developing and applying chemoproteomic workflows that support key stages of compound progression - from target identification and ligand library screening to cellular target engagement and selectivity profiling. Violette earned her PhD in structural and functional biology from Toulouse III University and completed her postdoctoral research at Utrecht University. Both focused on advanced proteomic strategies to investigate protein networks, cellular mechanisms and post-translational modifications.</p></blockquote></div>

Technology Networks: Unlocking High-Value Targets: The Power of Chemoproteomics and Covalent Mass Spectrometry

Unlocking High-Value Targets: The Power of Chemoproteomics and Covalent Mass Spectrometry

Learn how Evotec integrates high-throughput MS and chemoproteomics to identify and validate covalent inhibitors in modern drug discovery.

Power of Chemoproteomics and Covalent Mass Spectrometry

<div><div container-id="cq-colctrl-lt0" comp-id="A1"><div><p><strong>As the demand for greater accuracy and efficiency in genetic analysis grows, new approaches are needed to overcome the blind spots of conventional sequencing methods. This webinar will showcase a fully automatable workflow that integrates Agilent SureSelect hybrid capture, Agilent automated electrophoresis systems for sample quality control with PacBio HiFi long-read sequencing.</strong></p><p>In addition to discussing workflow, we’ll share case studies where long reads play a fundamental role in identifying genetic variants that may be missed by conventional sequencing in research studies.</p><h4><strong>Join us to learn how targeted long-read sequencing:</strong></h4><ul><li>Focuses on genes and regions of interest in genetic research, while reducing costs and boosting sequencing depth at key loci.</li><li>Overcomes the limitations of short-read technologies, including challenges with pseudogenes, homologous loci, structural variants, complex transcript isoforms, splicing events, and difficult regions such as repetitive or GC-rich sequences.</li><li>Enhances both analytical performance and laboratory efficiency through automation.</li></ul><h4><strong>Key learning objectives:</strong></h4><ul><li>Gain practical insights into implementing an automated targeted long-read sequencing workflow in the laboratory.</li><li>Identify the genetic mutation types best suited for targeted long-read sequencing approaches.</li><li>Understand the analytical advantages of long-read sequencing compared with conventional short-read methods.</li></ul><h4><strong>Who should attend?</strong></h4><ul><li>Lab directors, molecular pathologists, research scientists, clinical lab technicians, and anyone running or interested in running NGS workflows.</li></ul><h5><strong>Certificate of attendance</strong></h5><ul><li>If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.</li><li>If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.</li></ul><p><i>For Research Use Only. Not for use in diagnostic procedures. PR7003-294</i></p><blockquote><p><strong>Presenter: </strong>Iván Lesende Rodríguez, PhD (Chief Product Officer, Health in Code)</p><p>Iván Lesende Rodríguez is a senior genomics and bioinformatics leader with over 15 years of experience in NGS, omics data analysis, and genetic diagnostics. He completed his PhD jointly at the University of A Coruña (UDC) and University College London (UCL), focusing on molecular mechanisms of disease and omics analyses. In 2010, he joined Health in Code as a Sequencing Specialist, contributing to the early implementation of NGS workflows. He later joined Agilent Technologies (2015), where he held multiple roles, developing tailored NGS solutions for clients. Since 2025, as Chief Product Officer (CPO) at Health in Code, he leads the company’s product strategy and innovation.</p><p><strong>Presenter:&nbsp;</strong>Bettina Strauch, PhD (Product Manager - Automated Electrophoresis Product Portfolio, Agilent Technologies)</p><p>Bettina Strauch, PhD, is a product manager within the automated electrophoresis marketing team at Agilent Technologies and is based in Waldbronn, Germany. Since joining Agilent in 2018, she has been responsible for the automated electrophoresis product portfolio with a particular focus on the TapeStation systems. Prior to her role at Agilent, she held a postdoctoral research position at the Karlsruhe Institute of Technology, Germany, where she focused on toxicological in vitro research, gene expression profiling, and the development of high-throughput analytical techniques in molecular biology and biochemistry.</p><p><strong>Moderator:</strong> Matilde Marques (Life Sciences Assistant Editor, SelectScience)</p></blockquote></div></div></div>

SelectScience: How automation and integrated sample QC enhance a targeted long-read-sequencing workflow

How automation and integrated sample QC enhance a targeted long-read-sequencing workflow

Learn how automated workflows combining Agilent QC tools and PacBio long-read sequencing enhance accuracy, efficiency, and variant detection in genetics

Automation & QC Boost Targeted Long-Read Sequencing

<div><p><strong>Characterizing size variants in biotherapeutic proteins and peptides, such as GLP-1 receptor agonists, monoclonal antibodies (mAbs), and bispecific antibodies, can be difficult, but it doesn’t have to be. Accurate measurement of size variants is essential for obtaining critical quality attribute (CQA) information. These variants can have a significant impact on the safety, efficacy, and stability of biotherapeutic drugs.</strong></p><p>Join us for a discussion on how size-exclusion chromatography (SEC) can be used to obtain CQA data of proteins and peptides, and how to effectively pair SEC with multi-angle light scattering (SEC-MALS) and mass spectrometry (SEC-MS) for in-depth characterization. You’ll also gain insights into fit-for-purpose, SEC column technologies designed to simplify size variant analysis and deliver reproducible, high-quality results on any UPLC, UHPLC, or HPLC platform.</p><h4><strong>Key Learning Objectives</strong></h4><ul><li>How to effectively use SEC for protein and peptide size variant analyses</li><li>How to select the appropriate SEC column based on application and LC system</li><li>Learn the benefits and differences between denaturing and non-denaturing SEC methods</li><li>How to leverage SEC-MALS and SEC-MS to gain deeper insights from your data</li></ul><blockquote><p><strong>Presenter:</strong> Bill Warren (Principal Consultant Chemistry Product Manager, Waters Corporation)</p><p>Bill received his Masters in Microbiology and Immunology from University of Louisville School of Medicine. In 1986, joined Waters Corporation as a senior applications chemist involved with the research and development of HPLC, FPLC, and Capillary Electrophoresis applications for the analysis and purification of proteins, peptides, and nucleic acids. Bill currently is a Principal Consultant Product Manager whose responsibilities involve assisting in the development and commercialization of innovative reagents and chromatography-based technologies for the separation, purification, and characterization of biological molecules.</p></blockquote></div>

Waters Corporation: The Art of Separation: SEC for Biotherapeutic Proteins and Peptides

The Art of Separation: SEC for Biotherapeutic Proteins and Peptides

Explore SEC, SEC-MALS, and SEC-MS for biotherapeutic size variant analysis. Gain practical insights into column selection, CQAs, and data interpretation.

SEC for Biotherapeutic Proteins and Peptides

<p><strong>We are excited to invite you to our live webinar on the ZenoTOF 8600 system, a revolutionary technology designed to take your omics research to the next level. Don’t miss this opportunity to explore how the ZenoTOF 8600 system can strengthen your omics research workflows.</strong></p><h5><strong>Key highlights:</strong></h5><ul><li>Ultra-high sensitivity in an accurate mass platform</li><li>High-energy EAD extends electron-based fragmentation capabilities with up to <strong>50 eV</strong></li><li>Scan speeds of up to <strong>858 Hz</strong> using ZT Scan DIA 2.0, with extended mass range and adaptable collision energies suitable for all molecule types</li></ul><blockquote><p><strong>Presner: </strong>Dr. Dipankar Malakar (Application Support Manager, SCIEX India)</p></blockquote>

SCIEX: ZenoTOF 8600 system: the game-changing technology in omics research

ZenoTOF 8600 system: the game-changing technology in omics research

Discover how the ZenoTOF 8600 delivers ultra-high sensitivity, EAD fragmentation, and fast ZT Scan DIA 2.0 to advance modern omics research.

Related content

Oligos Made Easy - Part 3: IP-RP

News from LabRulezLCMS Library - Week 08, 2026

Why Is It Necessary to Dry the SPE Sorbent Before Elution?